SynthesisUnited European gastroenterology journal2020
Response and relapse rates after treatment with long-acting somatostatin analogs in multifocal or recurrent type-1 gastric carcinoids: A systematic review and meta-analysis.
Synthesis in United European gastroenterology journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 31 citations in OpenAlex.
- Clinical Outcomes of Antrectomy for Patients With Multiple Type I Gastric Neuroendocrine Tumors: A Case Series.DEN open · 2027Article
- Progression after endoscopic treatment for type I gastric neuroendocrine tumors: A single-center retrospective study.World journal of gastroenterology · 2026Article
- Endoscopic submucosal dissection with deliberate muscularis propria exposure for curative resection of a large type 1 gastric neuroendocrine tumor: a case report.Frontiers in oncology · 2026Article
- Current Medical Controversies in Zollinger-Ellison Syndrome.Biomedicines · 2025Review
- Controversies in NEN: An ENETS position statement on the endoscopic management of localised gastric, duodenal and rectal neuroendocrine neoplasms.Journal of neuroendocrinology · 2025Review
- Management of type I gastric-neuroendocrine tumors: the less the better?Frontiers in endocrinology · 2025Article
- Gastric neuroendocrine neoplasms: analysis of a cohort of patients followed at the Brazilian National Cancer Institute.Endocrine oncology (Bristol, England) · 2025Article
- Unraveling the Mysteries of Autoimmune Gastritis.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2024Review
- When rare diseases crisscross within the same patient: von Hippel-Lindau and type 1 gastric neuroendocrine tumor.Hormones (Athens, Greece) · 2024Review
- Management of type 1 gastric neuroendocrine tumors: an 11-year retrospective single-center study.BMC gastroenterology · 2023Article
- Therapeutic Challenges for Gastric Neuroendocrine Neoplasms: Take It or Leave It?Medicina (Kaunas, Lithuania) · 2023Review
- Gastric neuroendocrine tumors in aWorld journal of gastrointestinal oncology · 2023Article
- Endoscopic techniques for gastric neuroendocrine tumors: An update.World journal of gastrointestinal endoscopy · 2023Review
- Chronic Treatment with Somatostatin Analogues in Recurrent Type 1 Gastric Neuroendocrine Tumors.Biomedicines · 2023Article
- Gastric neuroendocrine neoplasms: a primer for radiologists.Abdominal radiology (New York) · 2022Review
- Therapeutic strategies for gastroenteropancreatic neuroendocrine neoplasms: State-of-the-art and future perspectives.World journal of gastrointestinal surgery · 2022Article
- Role of Somatostatin Signalling in Neuroendocrine Tumours.International journal of molecular sciences · 2022Review
- New Developments in Gastric Neuroendocrine Neoplasms.Current oncology reports · 2022Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundType-1 gastric neuroendocrine tumors represent a recurring disease and long-acting somatostatin analogs can inhibit both gastrin release and endocrine cell proliferation. The efficacy and timing of this treatment are still unclear. We performed a systematic review of the literature to clarify the role of somatostatin analog treatment in type-1 gastric neuroendocrine tumors.
methodsA computerized literature search was performed using relevant keywords to identify all the pertinent articles published in the last 15 years.
resultsEight studies were included in this systematic review on somatostatin analogs in type-1 gastric neuroendocrine tumors. A complete response rate ranged from 25-100%. When only the six prospective studies were considered, no significant heterogeneity was observed, and the pooled cumulative complete response rate was 84.5% (confidence interval 73.8-92.8). Three studies evaluated the type-1 gastric neuroendocrine tumor recurrence, with a cumulative relapse rate of 30.2% (confidence interval 13.1-50.6) after 34 months.
conclusionSomatostatin analogs, namely lanreotide and octreotide, have an excellent response rate, with a good safety profile in selected type-1 gastric neuroendocrine tumors, which cannot be safely managed by endoscopic follow-up or resection due to multiple or frequently recurring disease. After therapy discontinuation, the cumulative relapse rate observed after a median 34-month follow-up was relatively high (30.2%).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.